Dr. Stephen Munk has been with Ash Stevens Inc. since 1997, serving as President since 1998 and CEO since 2001. He is experienced in drug discovery, development, and manufacturing both as a scientist and as a manager. Prior to joining Ash Stevens, Dr. Munk worked at Allergan, Inc. as a drug discovery scientist and subsequently as the co-team leader of the adrenergic drug discovery team. Under Dr. Munk’s stewardship, Ash Stevens has received ten regulatory approvals for the manufacture of novel drug substances to treat serious life-threatening conditions. These approvals include bortezomib, clofarabine, 5-azacitidine, amotosalen, and ponatinib.